Chief Financial OfficerCIK 0001905248
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 0 | Espinoza OctavioChief Financial Officer |  LGNDLIGAND PHARMACEUTICALS INCOption exercise · 10b5-1 plan | M | — 16.2K sh | Aug 14, 2026 traded Aug 12, 2026 | |
Espinoza OctavioChief Financial Officer |
| LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan |
| M |
| — 7,171 sh |
| Aug 14, 2026 traded Aug 12, 2026 |
| 10 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $855K 16.2K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $145K 2,074 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $160K 2,869 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 2 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $410K 7,171 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $230K 3,348 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 24 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $9.24M 31.6K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 2,869 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 3,348 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 2,074 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 11 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Other acquisition or disposition | J | $2,732 17 sh | Jul 6, 2026 traded Jun 30, 2026 |
| 2 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | $49K 764 sh | May 28, 2026 traded May 27, 2026 |
| 2 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | — 764 sh | May 28, 2026 traded May 27, 2026 |
| 2 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | — 972 sh | May 28, 2026 traded May 27, 2026 |
| 5 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | $51K 972 sh | May 28, 2026 traded May 27, 2026 |
| 19 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Grant or award | A | — 4,933 sh | Mar 27, 2026 traded Mar 2, 2026 |
| 15 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Grant or award | A | — 23.5K sh | Mar 27, 2026 traded Mar 2, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 2,405 sh | Mar 13, 2026 traded Mar 11, 2026 |
| 18 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $688K 3,057 sh | Mar 13, 2026 traded Mar 11, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $223K 2,405 sh | Mar 13, 2026 traded Mar 11, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 466 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 14 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $136K 668 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $94K 1,607 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $38K 466 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 14 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $139K 699 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 11 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $11K 53 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 14 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $140K 698 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 14 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $192K 950 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 14 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $141K 697 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 17 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $300K 1,457 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 21 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $329K 1,588 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 21 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $511K 2,457 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 21 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $713K 3,413 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 1,607 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 14 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $152K 743 sh | Mar 6, 2026 traded Mar 4, 2026 |
| 14 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Other acquisition or disposition | J | $765 8 sh | Jan 6, 2026 traded Dec 31, 2025 |
| 5 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | — 285 sh | Dec 18, 2025 traded Dec 16, 2025 |
| 5 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | — 181 sh | Dec 18, 2025 traded Dec 16, 2025 |
| 13 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | — 652 sh | Dec 18, 2025 traded Dec 16, 2025 |
| 5 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | — 69 sh | Dec 18, 2025 traded Dec 16, 2025 |
| 8 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | $60K 652 sh | Dec 18, 2025 traded Dec 16, 2025 |
| 8 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | $63K 1,194 sh | Dec 18, 2025 traded Dec 16, 2025 |
| 5 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | $3,948 69 sh | Dec 18, 2025 traded Dec 16, 2025 |
| 5 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | — 1,194 sh | Dec 18, 2025 traded Dec 16, 2025 |
| 5 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | $19K 181 sh | Dec 18, 2025 traded Dec 16, 2025 |
| 5 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | $18K 285 sh | Dec 18, 2025 traded Dec 16, 2025 |
| 36 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Open-market sale | SELL | $340K 1,804 sh | Dec 16, 2025 traded Dec 12, 2025 |
| 19 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Tax withholding | F | $344K 1,862 sh | Dec 9, 2025 traded Dec 5, 2025 |